Former AXA Framlington Biotechnology fund manager Andy Smith has joined biopharma specialist Mann Bioinvest to launch an income-focused fund in the coming weeks.
The Magna BioPharma Income fund, slated to launch around the end of Q1 2013, will be managed by Smith, with key decisions overseen by an investment committee. Boutique equity house Charlemagne Capital...
Yellen hopes unwinding will be like 'watching paint dry'
Sold property business
New CEO David Barron's first
Promises "proportionality" for firms that have taken "sufficient steps"
The sectors that have weathered the storm over the years